Differential expression of programmed death-1 and its ligand, programmed death ligand-1 in oral squamous cell carcinoma with and without oral submucous fibrosis

被引:10
|
作者
Quan, Hongzhi [1 ,2 ,3 ,4 ,5 ,6 ]
Liu, Sixuan [1 ,2 ,3 ,4 ,5 ,6 ]
Shan, Zhongyan [1 ,2 ,3 ,4 ,5 ,6 ]
Liu, Ziyi [1 ,2 ,3 ,4 ,5 ,6 ]
Chen, Tianjun [1 ,2 ,3 ,4 ,5 ,6 ]
Hu, Yanjia [1 ,2 ,3 ,4 ,5 ,6 ]
Yao, Zhigang [1 ,2 ,3 ,4 ,6 ,7 ]
Fang, Liangjuan [8 ,9 ]
机构
[1] Cent South Univ, Hunan Key Lab Oral Hlth Res, Changsha 410008, Hunan, Peoples R China
[2] Cent South Univ, Hunan 3D Printing Engn Res Ctr Oral Care, Changsha 410008, Hunan, Peoples R China
[3] Cent South Univ, Hunan Clin Res Ctr Oral Major Dis & Oral Hlth, Xiangya Stomatol Hosp, Changsha 410008, Hunan, Peoples R China
[4] Cent South Univ, Xiangya Sch Stomatol, Changsha 410008, Hunan, Peoples R China
[5] Cent South Univ, Dept Oral Maxillofacial Surg, Xiangya Stomatol Hosp, Changsha 410008, Hunan, Peoples R China
[6] Cent South Univ, Sch Stomatol, Changsha 410008, Hunan, Peoples R China
[7] Cent South Univ, Xiangya Stomatol Hosp, Dept Oral Pathol, Changsha 410008, Hunan, Peoples R China
[8] Cent South Univ, Xiangya Hosp, Dept Neurol, Changsha 410008, Hunan, Peoples R China
[9] Cent South Univ, Key Lab Hunan Prov Neurodegenerat Disorders, Changsha 410008, Hunan, Peoples R China
基金
中国博士后科学基金;
关键词
Oral squamous cell carcinoma; Oral submucous fibrosis; Programmed death ligand-1; Programmed death 1; Prognosis; PD-L1; EXPRESSION; CANCER; MICROENVIRONMENT; BLOCKADE; GRADE;
D O I
10.1016/j.archoralbio.2020.104916
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
Objective: The aim of our study was to investigate the expression of programmed death ligand-1 (PD-L1)/programmed death-1 (PD-1) between oral squamous cell carcinoma (OSCC) patients with and without oral submucous fibrosis (OSF), and its correlation with clinic-pathologic features and its prognostic value. Methods: PD-L1 and PD-1 expression was evaluated by immunohistochemical staining, double immunofluorescent staining and real-time PCR, and the correlation of PD-L1/PD-1 expression with clinical outcome was assessed. Results: The level of PD-L1 expression was significantly higher in OSCC with OSF than in OSCC without OSF = 0.006). Moreover, PD-L1 expression was strongly correlated with lymph node metastasis (p = 0.016), and advanced tumor stage (p = 0.030). Increased PD-L1 expression was positively correlated with the incidence of OSCC with OSF = 0.006, p = 0.008, respectively). PD-L1 expression was an independent marker of unfavorable prognosis (p = 0.035, p = 0.048, respectively). High PD-L1 expression had a significantly worse outcome in OSCC patients with OSF (p = 0.014). Double immunofluorescent staining showed that OSCC with OSF were more strongly expressed both PD-L1 and PD-1 than OSCC without OSF. Moreover, the expression of PD-L1 were upregulated in OSCC tissues than normal control (p = 0.0422), and both PD-L1 and PD-1 was significantly higher in OSCC with OSF than OSCC without OSF tissues (p = 0.0043 and, p = 0.0012, respectively). Conclusions: The present study suggested that PD-L1 may be an unfavorable indicator for prognosis. PD-L1/PD-1 signaling might play an important role in the malignant transformation of OSF, and targeting PD-L1/PD-1 signaling may be a new therapeutic strategy for OSCC, especially in OSCC patients with OSF.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Programmed death ligand-1/programmed death-1 inhibition therapy and programmed death ligand-1 expression in urothelial bladder carcinoma
    Yu Wei-Bo
    Rao Jian-Yu
    [J]. 慢性疾病与转化医学(英文), 2019, 5 (03) : 170 - 177
  • [2] Programmed death-1 and programmed death ligand-1 blockade for advanced urothelial carcinoma
    Guo, Jhe-Cyuan
    Tsai, Yu-Chieh
    Pu, Yeong-Shiau
    [J]. UROLOGICAL SCIENCE, 2019, 30 (01) : 2 - 7
  • [3] Transarterial chemoembolisation enhances programmed death-1 and programmed death ligand-1 expression in hepatocellular carcinoma
    Montasser, A.
    Beaufrere, A.
    Cauchy, F.
    Soubrane, O.
    Colnot, N.
    Tessiore, S.
    Albuquerque, M.
    Paradis, V.
    [J]. VIRCHOWS ARCHIV, 2019, 475 : S20 - S20
  • [4] Association of Programmed Death Ligand-1 Overexpression with the Grade and Stage of Oral Squamous Cell Carcinoma
    Qureshi, Zeeshan Mustafa
    Qamar, Samina
    [J]. JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, 2020, 30 (06): : 662 - 664
  • [5] Expression of programmed death ligand-1 and programmed death-1 in samples of invasive ductal carcinoma of the breast and its correlation with prognosis
    Zhou, Tingting
    Xu, Di
    Tang, Bufu
    Ren, Yanling
    Han, Yiru
    Liang, Gege
    Wang, Jing
    Wang, Ling
    [J]. ANTI-CANCER DRUGS, 2018, 29 (09) : 904 - 910
  • [6] Expression patterns of programmed death-1 and programmed death-1 ligand-1 on T cells in gastric cancer
    Kim, Ji-Hyun
    Kim, Shinn-Young
    Shin, Eun-Young
    Jung, Ji-Han
    Choi, Hyun-Joo
    Jun, Kyong-Hwa
    [J]. ONCOLOGY LETTERS, 2019, 18 (03) : 2661 - 2669
  • [7] Expression of programmed death ligand-1 and programmed death 1 in hepatocellular carcinoma and its clinical significance
    Long, J.
    Qu, Tao
    Pan, X. F.
    Tang, X.
    Wan, H. H.
    Qiu, P.
    Xu, Yan-Hua
    [J]. JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2018, 14 : S1188 - S1192
  • [8] Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer
    Ohigashi, Y
    Sho, M
    Yamada, Y
    Tsurui, Y
    Hamada, K
    Ikeda, N
    Mizuno, T
    Yoriki, R
    Kashizuka, H
    Yane, K
    Tsushima, F
    Otsuki, N
    Yagita, H
    Azuma, M
    Nakajima, Y
    [J]. CLINICAL CANCER RESEARCH, 2005, 11 (08) : 2947 - 2953
  • [9] A Comparative Study to Assess the Increased Expression of Programmed Cell Death-1 (PD1) and Programmed Cell Death- Ligand-1 (PDL1) in Oral Potentially Malignant Disorders and Oral Squamous Cell Carcinoma
    Srivastava, Sonalika
    Sinha, Abhishek
    Srivastava, Sunita
    Mishra, Anuj
    [J]. JOURNAL OF INDIAN ACADEMY OF ORAL MEDICINE AND RADIOLOGY, 2023, 35 (04) : 468 - 472
  • [10] Programmed cell death-1 and programmed cell death ligand-1 antibodies-induced dysthyroidism
    Jaafar, Jaafar
    Fernandez, Eugenio
    Alwan, Heba
    Philippe, Jacques
    [J]. ENDOCRINE CONNECTIONS, 2018, 7 (05): : R196 - R211